This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

SARS-CoV-2 Nucleocapsid Protein Panel

By Diagnostics

COMING SOON

Use of the SARS-CoV-2 Nucleocapsid Protein Panels with rapid diagnostic tests can support benchmarking of antigen-detection diagnostic tests at any stage of the product life cycle

While studies are underway to evaluate the clinical performance of SARS-CoV-2 rapid diagnostic tests (RDTs), comparison of results across studies can be complicated by differences in study designs, recruitment strategies, prevalence within the populations, and user-product interactions. To address these challenges, PATH is producing uniform panels for nucleocapsid antigen RDTs that will improve the quality of assessment for test developers and offer a degree of comparability of diagnostic tests for a variety of stakeholders.

Utilizing a panel of standardized and uniform reagents enables comparability of analytical performance data across SARS-CoV-2 antigen RDTs, thus providing a benchmark. The SARS-CoV-2 Nucleocapsid Protein Panel provides an essential tool for developers to rapidly assess and verify basic performance characteristics of their technologies. The panels can also be leveraged by ministries of health and donors who are interested in evaluating technologies to support procurement decision-making.

Click here to express your interest in obtaining the SARS-CoV-2 Nucleocapsid Protein Panel. Please be aware that this product is in late development and that submitting your interest does not guarantee access to the panels.

Composition

The SARS-CoV-2 Nucleocapsid Protein Panel is composed of 50 members containing panel diluent controls and a range of concentrations of irradiated (inactivated) SARS-CoV-2 virus, recombinant N antigens, and SARS-CoV-2-negative nasal eluate and other human common coronaviruses (not inactivated). The panel does not include SARS-CoV-2-positive clinical specimens.

Once available, the panels can be shipped to manufacturers blinded, or, if preferred, manufacturers can provide their RDTs to PATH to conduct the benchmarking tests at its facilities in Seattle, Washington, USA. Detailed instructions for use will be provided with the panels.

For access to clinical specimens or to learn more about PATH’s full benchmarking activities please contact SpecimenRepository@path.org.

Analytical panel against which to benchmark the performance of SARS-CoV-2 antigen rapid diagnostic tests

Analytical panel against which to benchmark the performance of SARS-CoV-2 antigen rapid diagnostic tests

Submit a preliminary request

Please be aware that this product is in late development and that submitting your interest does not guarantee access to the panels.

Click here

The Bill & Melinda Gates Foundation provided funding to support development and feasibility of the SARS-CoV-2 Nucleocapsid Protein Panel.